Gene-Edited immune cells take on Hard-to-Treat blood cancers

NCT ID NCT05643742

First seen Nov 03, 2025 · Last updated Apr 24, 2026 · Updated 20 times

Summary

This study tests a new treatment called CTX112 for people with B-cell blood cancers that have come back or not responded to standard therapy. CTX112 uses CRISPR gene editing to modify donor immune cells so they can better find and attack cancer cells. The trial has two parts: first, finding the safest dose, then expanding to see how well it works in up to 120 adults.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Alfred Health

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • Royal Prince Alfred

    RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • SCRI

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Sir Charles Gairdner Hospital

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • University of Kansas

    RECRUITING

    Westwood, Kansas, 66205, United States

  • University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

  • Washington University

    RECRUITING

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.